MedTrace Logo

Viral Infection of HSPC Impacts Hematopoiesis

NCT06458504 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2025-03-20

No results posted yet for this study

Summary

We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.

Conditions

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Claude CAPRON, MD, PhD · Laboratory of Immunology, Ambroise Paré hospital - APHP

  • Fernando REAL, PhD · Center for Infection and Immunity of Lille, INSERM U1019 - CNRS UMR9017, Institut Pasteur de Lille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-25
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06458504 on ClinicalTrials.gov